Health Care Technology
Company Overview of DNAnexus, Inc.
DNAnexus, Inc. provides cloud-based genome informatics and data management tools for enterprises and organizations that are engaged in the development and delivery of genomic medicine. The company’s platform enables the companies to analyze raw sequencing data; integrate genomic data with clinical and other phenotypic data; and collaborate seamlessly. It serves biopharmaceutical companies, genome centers, diagnostic test providers, and others. The company has a strategic alliance with WuXi NextCODE Genomics. DNAnexus, Inc. was founded in 2009 and is based in Mountain View, California.
1975 West El Camino Real
Mountain View, CA 94040
Founded in 2009
Key Executives for DNAnexus, Inc.
Chief Executive Officer and Director
Co-Founder and Board Observer
Co-Founder and Board Observer
Compensation as of Fiscal Year 2016.
DNAnexus, Inc. Key Developments
M2Gen Selects DNAnexus to Manage Molecular Data for ORIEN Avatar Research Program
Sep 22 16
DNAnexus Inc. announced that M2Gen has adopted the company’s cloud translational science platform to support molecular data access, management, collaboration, and analysis for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program. This initiative unites academic cancer centers and pharmaceutical companies in pursuit of shared translational oncology goals: the development of more precise cancer treatments for patients. The ORIEN Avatar Research Program provides a secure and innovative collaborative environment linking pharmaceutical companies, including Takeda and Celgene, and prominent cancer centers, including co-founders Moffitt Cancer Center in Tampa, Fla. and The Ohio State University Comprehensive Cancer Center "Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio. Participating cancer researchers contribute samples and disease information from consenting, participating patients, and receive rich molecular data plus access to a rich network of potential collaborators.
DNAnexus, Inc. Presents at UBS Genomics 2.0 Summit, Aug-11-2016 01:15 PM
Aug 7 16
DNAnexus, Inc. Presents at UBS Genomics 2.0 Summit, Aug-11-2016 01:15 PM. Venue: St. Regis Deer Valley, Park City, Utah, United States. Speakers: Brad Sitko, Vice President of Finance & Corporate Development, David Shaywitz, Chief Medical Officer.
DNAnexus Platform Supports Clinical Whole Genome Sequencing Service from Garvan Institute
Jul 27 16
DNAnexus Inc. announced that the Garvan Institute of Medical Research in Sydney, Australia has selected the DNAnexus Platform to power its new Genome.One clinical whole genome testing company. Garvan uses DNAnexus to manage, analyze, and secure the massive quantities of genomic data generated by the center’s leading NGS technology including Illumina’s HiSeq X Ten. Garvan uses the DNAnexus Platform to support complex, multi-institution global collaborations as well as high-speed, cost-efficient analysis and delivery of sequence data across a worldwide network. The Garvan Institute’s new company, Genome.One offers clinical whole-genome sequencing services for diagnosing rare and genetic conditions. Genome.One represents the clinical extension of the Kinghorn Centre for Clinical Genomics (KCCG), and benefits from the nearly 18-month relationship between DNAnexus and the Garvan Institute. Rather than traditional tests that analyze a single gene or multi-gene panel, this new service has the capacity to sequence and analyze the entire genome, including all 20,000 genes, in a single test. The new service provides a fast, accurate and comprehensive service, and is expected to increase the diagnosis rates of rare disorders from around twenty percent to 46%.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|